Business success tips

Analysisbusiness

We make analysis. You do business.

Emma Walmsley’s prescription for GSK

Share on your social media:

In 2017 GSK named a new CEO, Emma Walmsley. It turned out that she is just what the company needed.

uncaptioned

Hal Barron (seated), CSO, GSK & Emma Walmsley, CEO, GSK

Emma Walmsley’s roots are linked to a French cosmetics giant L’Oréal, where she spent 17 years in a range of jobs in Paris, London and New York before travelling to China. There, she worked to accelerate the growth of global brands including L’Oréal Paris, Maybelline and Garnier, as well as Chinese skincare brand Mininurse. Emma Walmsley was seen in the eyes of many business leaders as a rising star in the industry and a natural contender for future positions in L’Oréal’s senior global management. Her decision to leave L’Oréal shocked insiders in China’s luxury community.

After a networking lunch with Andrew Witty, the CEO of British pharmaceuticals giant GlaxoSmithKline (GSK), her life turned upside down. Witty offered Walmsley a position of GSK’s global consumer healthcare business president. At that time, the unit was generating £5bn (€5.67bn) in net sales and was one of the company’s three main pillars alongside pharmaceuticals and vaccines.

Emma Walmsley has taken unprecedented steps to breathe new life into struggling GSK.

Emma Walmsley was firstly reserved about taking the job. She worried that she was not really prepared for the new responsibilities. Despite her doubts, she decided to take the opportunity. She moved back from China to her native England.

Already after six years GSK and Emma Walmsley again shocked the market. In 2017 Emma Walmsley was promoted to GSK’s CEO. GSK, the name behind Sensodyne toothpaste, lung treatment Advair, shingles vaccine Shingrix and many other products, entered into a whole new era. In FY 2018 the company generated £30.8bn in net sales and £5.5bn EBIT, with over 95,000 employees.

Emma – the “revitalizing” outsider

Since becoming the CEO of GSK, Emma Walmsley has faced a rocky transition period. Investors were questioning earnings expectations and GSK’s dividend policy. This created “real pressures” on the share price towards the end of 2017. As a response, GSK’s London-listed shares dropped from 1,650p (€18.67) at the time Walmsley took the helm to 1,290p (€14.60) at the end of 2017 and early 2018. Investors were questioning whether or not Emma is the person to address the company’s under-performance. Many of them didn’t really see the right person in her. Some major long-term investors, such as British fund manager Neil Woodfor, even sold all of their shares.

According to experts, the main reasons behind the poor company performance could be linked to R&D team and the company’s insistence on spreading its resources thinly over a large number of assets rather than zeroing in on a handful of potential blockbuster drugs. Roger Franklin, a Liberum analyst said that decision-making within the R&D organisation is slow, assets are languished in phase one and phase two studies for long periods, and there isn’t enough focus on assets that could really move the needle etc. Credit Suisse analysts went even further. They shocked with their opinion that they only see a sales potential of £1.2bn (€1.36bn) by 2022 from GSK’s pipeline, compared with an annual pharma and vaccines R&D spend of £3.4bn (€3.85bn).

Following a six-month listening tour, Emma Walmsley held a meeting with senior R&D executives to confront the issue of GSK’s lack of commercial successes. According to Fortune, Emma Walmsley had them watch a video of analysts outlining everything that was wrong with GSK’s R&D performance. After this, Emma Walmsley reportedly said: “Everything’s on the table here. The world is saying it’s broken. Let’s see if we can fix it.” And perhaps this was actually THE moment for her …

Since then, Emma Walmsley has totally refreshed GSK’s leadership, having changed about 40% of the top executives within months of becoming CEO. She gained respect from investors for bringing in well-known individuals. Emma Walmsley brought Hal Barron, ex president of R&D at tech giant Alphabet’s secretive anti-ageing start-up, Calico. The same Hal Barron, who has developed some of the biggest products in pharmaceuticals in the last couple of decades and is today one of the hottest names in terms of delivery and R&D. As Chief Scientific Officer and President of R&D, Barron immediately started to focus on topics such as speeding up the decision-making, making people accountable for their decisions, allocating resources to assets with the highest potential and so on. Another important new hire was Luke Miels, ex AstraZeneca’s executive. He was brought with the intention to fill the gap between the commercial aspects of a pharmaceutical business and the R&D organisation. Karenann Terrell, ex executive at Walmart, became GSK’s chief digital and technology officer.

GSK continued by terminating or divesting more than 30 drug development programmes in the process. They sold off the company’s rare disease unit and began a strategic review of its cephalosporins antibiotic business. Going forward, GSK strengthened its investments in oncology and immuno-inflammation while continuing to focus on its top therapy areas: respiratory conditions, HIV and infectious diseases.


Emma Walmsley visiting GSK’s production

Emma Walmsley pursued radical change at GSK. A change that was much needed for the serious business turnaround. She used her management expertise to begin a process of revitalizing the firm’s stagnation.

Financial Times was writing about her belief that having a fresh pair of eyes was actually incredibly helpful when deciding which therapy areas to be in or which assets to back, or which people to hire and fire. Perhaps it is even more important that she started to be convinced that she has the right to be at the top table and that she is genuinely happy with her new role and the fact that she is making a difference.

We must not forget also the fact that Emma Walmsley stands behind the decision to buy Novartis out of the consumer healthcare joint venture. GSK spent $13bn (€11.4bn) to take full control of the unit. Bringing all consumer revenues in house made it possible for the company to plan the next major business leap – MEGA merger with Pfizer, resulting in a cost savings of £0.5bn by 2022.

However, this was not the sole acquisition. Aside from the above, GSK also generated some positive buzz with a $300m (€263m) deal to partner with direct-to-consumer genetic testing company 23andMe. The partnership with the data-rich Silicon Valley company is expected to increase the chances of developing a blockbuster drug.

Furthermore, the company also acquired Tesaro, the maker of the ovarian cancer drug Zejula, for $5.1bn. The transaction is believed to strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in the area of oncology.

Emma Walmsley is shaping the future of one of the world’s biggest and oldest pharmaceutical firms at a crucial moment in its history. She indeed demonstrated that she will not shy away from tough decisions or new opportunities.

Although skeptics have doubted her ability to revive the struggling company, Emma Walmsley proved them wrong. Without any serious pharmaceutical experience, she is today the one that stands behind a major value creation steps of GSK. The share price performance since then and the decisions that she’s taken demonstrate that she has put the business on the right path. Forbes even named her as the most powerful woman in business outside the US.


Share on your social media:

29 thoughts on “Emma Walmsley’s prescription for GSK

  1. Have you ever considered writing an e-book
    or guest authoring on other blogs? I have a blog
    based on the same ideas you discuss and would love
    to have you share some stories/information. I know my subscribers would value your work.
    If you are even remotely interested, feel free to shoot me
    an e mail.

  2. I run a vape store directory and we have had a listing from a vape shop in the USA that likewise advertises CBD products. A Month later, PayPal has contacted use to claim that our account has been restricted and have asked us to take away PayPal as a payment solution from our vape store web directory. We do not retail CBD items like CBD oil. We only provide marketing and advertising solutions to CBD companies. I have checked out Holland & Barrett– the UK’s Major Health Retailer and if you take a close look, you will witness that they sell a pretty extensive series of CBD goods, specifically CBD oil and they also happen to take PayPal as a payment method. It seems that PayPal is applying contradictory standards to different companies. Due to this restriction, I can no longer take PayPal on my CBD-related website. This has constricted my payment choices and now, I am heavily dependent on Cryptocurrency payments and direct bank transfers. I have spoken with a lawyer from a Magic Circle law practice in London and they explained that what PayPal is doing is definitely not legal and inequitable as it should be applying a consistent criterion to all firms. I am still to check with another lawyer from a US law practice in The city of london to see what PayPal’s legal position is in the United States. In the meantime, I would be highly appreciative if anyone here at targetdomain could offer me with substitute payment processors/merchants that work with CBD firms.

  3. I look after a vape store website directory and we have had a posting from a vape shop in the USA that likewise advertises CBD goods. A Month later, PayPal has written to use to say that our account has been restricted and have requested us to get rid of PayPal as a payment method from our vape store directory site. We do not sell CBD items such as CBD oil. We simply provide advertising and marketing services to CBD firms. I have checked out Holland & Barrett– the UK’s Well known Health and wellness Merchant and if you take a close look, you will see that they offer a surprisingly substantial stable of CBD items, specifically CBD oil and they also happen to accept PayPal as a settlement solution. It emerges that PayPal is employing twos sets of rules to many different firms. Because of this limitation, I can no longer take PayPal on my CBD-related website. This has restrained my payment choices and presently, I am intensely dependent on Cryptocurrency payments and direct bank transfers. I have checked with a barrister from a Magic Circle law firm in London and they explained that what PayPal is undertaking is definitely not legal and discriminatory as it ought to be applying a consistent benchmark to all companies. I am still to consult a different attorney from a US law firm in London to see what PayPal’s legal position is in the USA. Meanwhile, I would be extremely appreciative if anyone here at targetdomain could provide me with different payment processors/merchants that work with CBD companies.

  4. I look after a vape shop website directory and we have had a listing from a vape store in the United States that additionally markets CBD product lines. A Month later, PayPal has contacted use to claim that our account has been restricted and have asked us to take away PayPal as a payment solution from our vape store directory. We do not sell CBD product lines like CBD oil. We merely offer online marketing professional services to CBD companies. I have taken a look at Holland & Barrett– the UK’s Top Health and wellness Retailer and if you take a good look, you will see that they sell a relatively extensive variety of CBD items, primarily CBD oil and they also happen to accept PayPal as a settlement method. It emerges that PayPal is employing twos sets of rules to many different companies. Due to this limitation, I can no longer accept PayPal on my CBD-related web site. This has restrained my payment possibilities and right now, I am heavily contingent on Cryptocurrency payments and straightforward bank transfers. I have talked with a solicitor from a Magic Circle law firm in The city of london and they explained that what PayPal is doing is absolutely unlawful and inequitable as it ought to be applying an uniform standard to all companies. I am yet to seek advice from one more legal representative from a US law practice in London to see what PayPal’s legal position is in the USA. Meanwhile, I would be highly appreciative if anybody here at targetdomain could provide me with substitute payment processors/merchants that deal with CBD companies.

Leave a Reply

Your email address will not be published.